Time-effect profile of antihypertensive agents assessed with trough/peak ratio, smoothness index and dose omission: An ambulatory blood pressure monitoring study with trandolapril vs. Quinapril

Fundamental and Clinical Pharmacology

Volumn 16, Issue 6, 2002, Pages 545-554

  Radauceanu, Anca ^a   Virion, Jean Marc ^a   Boivin, Jean Marc ^b   Zannad, Faiez ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b CIC General Practitioners Investigators Group   (France)

Author keywords

Ambulatory blood pressure monitoring; Angiotensin converting enzyme inhibitors; Hypertension

Indexed keywords

INDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; QUINAPRIL; TETRAHYDROISOQUINOLINE DERIVATIVE; TRANDOLAPRIL; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TIME; ANALYTICAL PARAMETERS; DISEASE SEVERITY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; INDOLES; ISOQUINOLINES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TETRAHYDROISOQUINOLINES; TIME FACTORS;

EID: 0036458401     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2002.00131.x     Document Type: Article

References (29)

1. White W.B. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit (2001) 6 63-72.
2. Ohkubo T. et al. Prediction of stroke by ambulatory blood pressure monitoring vs. screening blood pressure measurements in a general population: The Ohasama study. J Hypertens (2000) 18 847-854.
3. Lavery C.E. et al. Nonuniform nighttime distribution of acute cardiac events. Circulation (1997) 96 3321-3327.
4. Mancia G., Omboni S., Parati G. The importance of blood pressure variability in hypertension. Blood Press Monit (2000) 5 S9-15.
5. Meredith P.A., Perloff D., Mancia G., Pickering T. Blood pressure variability and its implications for antihypertensive therapy. Blood Press (1995) 4 5-11.
6. Zannad F. Practical relevance of the 24-hour trough/peak ratio of antihypertensive drugs. J Hypertens (1995) 13 (Suppl).
7. Mar J., Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: Hypertension stage, type of drug or therapeutic compliance? J Hypertens (2001) 19 (Suppl) 149-155.
8. Neutel J.M. The importance of 24-h blood pressure control. Blood Press Monit (2001) 6 9-16.
9. Detry J.M.R., Block P., De Backer G, Degaute JP. Patient compliance and therapeutic coverage: Comparison of amlodipine and slow release nifedipine in the treatment of hypertension. Eur J Clin Pharmacol (1995) 47 477-481.
10. Meredith P.A., Elliott H.L. FDA guidelines on trough/peak ratios in the evaluation of antihypertensive agents. United States Food and Drug Administration. J Cardiovasc Pharmacol (1994) 23 (suppl 5) S26-30.
11. Omboni S., Parati G., Zanchetti A., Mancia G. Calculation of trough/peak ratio of antihypertensive treatment from ambulatory blood pressure: Methodological aspects. J Hypertens (1995) 13 1105-1112
12. Rizzoni D. et al. Beyond trough:peak ratio: A new index of the smoothness of the antihypertensive effect of a drug. High Blood Press (1997) 6 111-115.
13. Mallion J.M. et al. Clinical value of ambulatory blood pressure monitoring. J Hypertyens (1999) 17 585-595.
14. Elliott H.L., Meredith P.A. Methodological considerations in calculation of the trough/peak ratio. J Hypertens (1994) 12 (suppl 8) S3-7.
15. Parati G. et al. The smoothness index: A new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens (1998) 16 1685-1691.
16. Leenen F.H.H., Fourney A., Notman G., Tanner J. Persistance of antihypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol (1996); 41 83-88.
17. O'Brien E., Mee F., Atkins N., O'Malley K. Accuracy of the SpaceLabs 90927 determined by the British Hypertension Society Protocol. J Hypertens (1991) 9 573-574.
18. Staessen J.A. et al. Determining the trough-to-peak ratio in parallel-group trials. Hypertension (1997) 29 659-667.
19. Meredith P.A., Elliott H.L. Trough/peak ratios for antihypertensive agents: Methodological considerations. Blood Press Monit (1996) 1 293-297.
20. Parati G. et al. Smoothness-index but not T/P ratio estimates balances 24-hour blood pressure control and predicts regression of organ damage by antihypertensive treatment. J Hypertens (1997) 15 (suppl 4) S7.
21. Zannad F., Matzinger A., Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens (1996) 9 633-643.
22. Peters D.C., Noble S., Plosker G.L. Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs (1998) 56 871-893.
23. Piepho R.W. Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm (2000) 57.
24. Zannad F. Trandolapril: How does it differ from other angiotensin convertingenzyme inhibitors. Drugs (1993) 46 (suppl 2) 172-182.
25. Wei L., Clauser E., Alhenc-Gelas F., Corvol P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem (1992) 267 13398-13405.
26. Bevilacqua M. et al. Affinity of angiotensin I-converting enzyme (ACE) inhibitors for N- and C-binding sites of human ACE is different in heart, lung, arteries, and veins. J Cardiovasc Pharmacol (1996) 28 494-499.
27. Rizzoni D. et al. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J Hypertens (2001) 19 703-711.
28. Meredith P.A. Trough/peak ratio and smoothness index for antihypertensive agents. Blood Pressure Monit (1999) 4 257-262.
29. Elliott H.L., Meredith P.A. Calculation of trough-to-peak ratio in the research unit setting. Advantages and disadvantages. Am J Hypertens (1996) 9 (10Pt2) 71S-75S.